Table 1

Dataset*	GEO access number or web location	Number of patients	% DFS data available	% OS data available	Reference
1	GSE1456	159	100	100	[22]
2	GSE2603	99	82.8	0	[23]
3	GSE6532	327	96.0	0	[24]
4	GSE3494	108^&	100	100	[25]
5	GSE7390	198	100	100	[26]
6	GSE11121	197	100	0	[27]
7	GSE12093	136	100	0	[28]
8	GSE2034	286	100	0	[29]
9	ArrayExpress:E-TABM-158	130	99.2	99.2	[30]
10	NKI (http://microarray-pubs.stanford.edu/wound_NKI/)	295	100	100	[31]
11	GSE17080	185	0	0	[32]
12	GSE3744	47	0	0	[33]

*Dataset 1 to 9, 11 and 12 are profiled using Affymetrix microarray, Dataset 11 using Agilent Oligo microarray. Dataset 1-10 are used to evaluate prognostic impact of FBXW7 expression. Dataset 1-10 was used for analysis of disease-free survival in Figure 2, 3, 5 and 6. Dataset 1, 4, 5, 9 and 10 was used for analysis of overall survival in Figure 2, 3, 5 and 6. Dataset 11 and 12 contains both normal and breast cancer samples. ^&There are total 251 patents in GSE3494, 143 of them overlapped with GSE6532 were removed.

Table 1: Information of gene expression datasets used in this study.